Plain English coverage of UK weight loss injections including Mounjaro, Wegovy and Ozempic — how they work, NHS access, private clinic costs and real patient experiences.
A new weight loss injection called CagriSema is producing results that are turning heads in obesity medicine. It combines two powerful ingredients into a single weekly jab — and early trial data suggests it could outperform both Ozempic and Mounjaro. Here is everything UK patients need to know right now.
Two injections. Both making headlines. Both changing lives — but they work differently and suit different people. Here is everything you need to know before you spend a penny.
The NHS has broadened who can receive Mounjaro on prescription, with new rules now covering patients with a BMI of 35 or above alongside qualifying health conditions. This change is already embedded in GP contracts across England. Here is exactly what has changed and whether you might now qualify.
NHS England has struck a new supply agreement with Eli Lilly that could dramatically expand access to Mounjaro on the NHS. Here is what we know so far, what it means for women currently paying privately, and the questions that still need answering.
We use cookies to understand how The Peptide Brief is used and to improve the site. You can accept analytics cookies, reject them, or manage your preferences.